NCT07267091Completed
The Burden of Lupus in Canada From a Patient Perspective: A Canadian Real-World PROxy Study
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
This study aims to capture the Canadian patient experience, burden, barriers, and treatment preferences. The findings will generate real-world evidence to support patient-centered care and guide healthcare providers, researchers, and decision-makers in improving support and treatment for people living with lupus.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 88 (actual)
- First submitted
- 24 Nov 2025
- Start date
- 3 Nov 2025
- Primary completion date
- 23 Jan 2026
- Lead sponsor
- PeriPharm
- Diseases
- Lupus (SLE)
- NCT number
- NCT07267091
What you commit to
- Study type: Observational
- Participants enrolled: 88
- From 3 Nov 2025 to the primary completion date, 23 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Participation in an interventional clinical trial for Lupus.
Who the study is looking for
- 18 years of age or older;
- Part of the Lupus Canada database;
- Self-identified as a patient with Lupus.
- Ability to read and understand English or French;
- Signature of informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROxy Network, an initiative of PeriPharm inc. Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.